VANCOMYCIN Drug Patent Profile

Which patents cover Vancomycin, and when can generic versions of Vancomycin launch?

Vancomycin is a drug marketed by Hikma, Fresenius Kabi Usa, Lupin Ltd, Orient Pharma Co Ltd, Pai Holdings, Strides Pharma, Watson Labs, Alkem Labs Ltd, Amneal, Aspiro, Avet Lifesciences, Eugia Pharma, Gland, Hikma Pharms, Hospira, Hospira Inc, Knack, Medimetriks Pharms, Meitheal, Mylan Labs Ltd, Plano Pharms, Sagent Pharms, Slate Run Pharma, Teva Pharms Usa, Xellia Pharms Aps, Samson Medcl, Steriscience, Zhejiang Novus Pharm, and Baxter Hlthcare. and is included in fifty-five NDAs. There are five patents protecting this drug.

This drug has forty-nine patent family members in twenty-nine countries.

The generic ingredient in VANCOMYCIN is vancomycin hydrochloride. There are twenty-two drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the vancomycin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vancomycin

A generic version of VANCOMYCIN was approved as vancomycin hydrochloride by FRESENIUS KABI USA on March 17^th, 1987.

Summary for VANCOMYCIN

International Patents:	49
US Patents:	5
Applicants:	29
NDAs:	55
Raw Ingredient (Bulk) Api Vendors:	37
Clinical Trials:	481
Patent Applications:	2,507
Drug Prices:	Drug price information for VANCOMYCIN
What excipients (inactive ingredients) are in VANCOMYCIN?	VANCOMYCIN excipients list
DailyMed Link:	VANCOMYCIN at DailyMed

See drug prices for VANCOMYCIN

See drug sales revenues for VANCOMYCIN

Recent Clinical Trials for VANCOMYCIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
McGill University Health Centre/Research Institute of the McGill University Health Centre	PHASE3
The Methodist Hospital Research Institute	NA
Nantes University Hospital	PHASE2

See all VANCOMYCIN clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for VANCOMYCIN

A07AA	Antibiotics
A07A	INTESTINAL ANTIINFECTIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

J01XA	Glycopeptide antibacterials
J01X	OTHER ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for VANCOMYCIN

VANCOMYCIN is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mylan Labs Ltd	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	091554-001	Sep 19, 2011	AP	RX	No	Yes
Mylan Labs Ltd	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	POWDER;INTRAVENOUS	209481-003	Jul 10, 2018	AP	RX	Yes	Yes
Hikma	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	203300-002	Aug 11, 2020	AP	RX	No	No
Fresenius Kabi Usa	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	062663-003	Jun 3, 1988	AP	RX	No	Yes
Teva Pharms Usa	VANCOMYCIN HYDROCHLORIDE	vancomycin hydrochloride	INJECTABLE;INJECTION	201250-002	Dec 23, 2015		DISCN	No	No

International Patents for VANCOMYCIN

See the table below for patents covering VANCOMYCIN around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	3542812
Mexico	387229	COMPOSICIONES ANTIBIÓTICAS (GLYCOPEPTIDE COMPOSITIONS)
Serbia	59851	KOMPOZICIJE GLIKOPEPTIDA (GLYCOPEPTIDE COMPOSITIONS)
Serbia	59851
Tunisia	2017000182	GLYCOPEPTIDE COMPOSITIONS

Market Dynamics and Financial Trajectory for Vancomycin

Last updated: March 3, 2026

What Is the Current Market Size and Growth Outlook for Vancomycin?

Vancomycin remains a critical antibiotic used for severe bacterial infections, especially those caused by methicillin-resistant Staphylococcus aureus (MRSA). In 2022, the global vancomycin market was valued at approximately USD 1 billion. The compound annual growth rate (CAGR) from 2022 to 2030 is projected at 4.2% (Grand View Research, 2023).

Factors driving growth include rising incidences of resistant infections, increased hospital-acquired infections, and expanding antibiotic treatment protocols. Competitive pressures from newer antibiotics, such as lipoglycopeptides and oritavancin, slightly temper market expansion but do not significantly displace vancomycin in critical care applications.

What Are Key Market Drivers and Challenges?

Drivers

• Antimicrobial Resistance (AMR): The World Health Organization (WHO) classifies MRSA as a critical priority pathogen, boosting demand for vancomycin (WHO, 2014). Resistance trends compel hospitals to maintain vancomycin as a first-line agent.
• Hospital and ICU Use: Vancomycin is a mainstay for severe infections such as pneumonia, bacteremia, and endocarditis, facilitating steady demand.
• Regulatory Support and Guidelines: US CDC guidelines recommend vancomycin for MRSA infections, reinforcing its clinical role.

Challenges

• Resistance Development: Vancomycin-intermediate (VISA) and resistant strains (VRSA) have appeared, leading to concerns over diminishing efficacy. The rate of VRSA remains below 1% globally but is rising in select regions.
• Toxicity Profile: Nephrotoxicity and ototoxicity limit broad and prolonged use, prompting cautious dosing protocols.
• Emerging Alternatives: Lipoglycopeptides (e.g., telavancin) and antibiotics like linezolid are competing, particularly in outpatient settings and for less severe infections.

How Does Patent Status and Generic Competition Affect Market Dynamics?

While original patents for vancomycin formulations expired decades ago, oversight on manufacturing quality under Good Manufacturing Practices (GMP) and pricing policies influence market concentration. Generic versions, introduced in late 20th century, dominate supply, maintaining competitive pricing. The absence of patent barriers means no significant patent cliffs or exclusivity periods.

What Are the Revenue and Cost Structures?

Revenue

Major pharmaceutical companies generate revenue primarily via generic drug sales to hospitals and pharmacy chains. Pricing varies globally but typically ranges between USD 1 to USD 10 per vial, depending on formulation and region.

Cost Structure

Costs hinge on raw materials (glycine derivatives), manufacturing complexity, regulatory compliance, and distribution. Production costs are relatively low due to established manufacturing processes; however, quality assurance adds to operational expenses.

What Future Trends Could Influence the Financial Trajectory?

Technological Innovations

Precision dosing tools, such as continuous infusion and therapeutic drug monitoring, optimize efficacy and safety, potentially expanding treatment applicability.

Policy and Reimbursement Changes

Increased antimicrobial stewardship programs may limit usage, constrain revenue growth, but also promote responsible use of existing antibiotics.

Resistance Management

Monitoring and containment efforts against VRSA and VISA strains are crucial. A rise in resistant strains would boost demand for newer antibiotics, possibly reducing vancomycin's market share over the long term.

Comparative Analysis with Similar Antibiotics

Parameter	Vancomycin	Linezolid	Oritavancin
Spectrum	Gram-positive	Gram-positive	Gram-positive
Route	IV	Oral/IV	IV
Cost per dose	USD 1–10	USD 50–100	USD 1,500 (single dose)
Resistance issues	Yes	Less	Rare

Vancomycin's cost-effectiveness and established efficacy sustain its market position despite emerging competition and resistance challenges.

Market Outlook and Investment Implications

The market will grow modestly through 2030 but faces saturation in developed regions. Emerging markets offer expanding opportunities due to increasing healthcare infrastructure. Companies investing in manufacturing capacity, quality control, and clinical research on resistance mitigation will benefit.

Control over supply chain quality and adherence to global health standards will influence profitability. Entry barriers remain low due to generic availability but demand for quality assurance sustains premium pricing in certain jurisdictions.

Key Takeaways

• The global vancomycin market is projected to grow at 4.2% CAGR, reaching USD 1.5 billion by 2030.
• Resistance development, toxicity concerns, and rising alternatives pose challenges.
• Generics dominate market supply, influencing pricing and margins.
• Technological and policy shifts could influence future demand and revenue.
• Investment opportunities exist in manufacturing excellence, especially targeting emerging markets.

FAQs

1. What are the primary resistance issues associated with vancomycin?
VRSA and VISA strains are emerging; resistance remains low but is increasing in some regions, potentially reducing the antibiotic's efficacy.

2. How does global demand vary across regions?
Developed regions like North America and Europe maintain steady demand through hospital use, whereas emerging markets show increasing consumption due to healthcare infrastructure expansion.

3. Are there new antibiotics poised to replace vancomycin?
Lipoglycopeptides and newer agents like oritavancin provide alternatives, especially for outpatient care and resistant infections, but vancomycin remains the standard for serious inpatient use.

4. What impact does antimicrobial stewardship have on vancomycin sales?
Stewardship programs aim to reduce unnecessary use, which can limit growth but also improve treatment outcomes and delay resistance.

5. What company strategies are effective in maintaining market share?
Focusing on quality manufacturing, compliance with regulatory standards, and adaptions to resistance patterns are key. Investment in clinical research and expanding supply chain capacity also enhances competitiveness.

---

References

[1] Grand View Research. (2023). Vancomycin Market Size, Share & Trends Analysis Report.
[2] World Health Organization. (2014). Antimicrobial resistance: Global report on surveillance.
[3] U.S. Centers for Disease Control and Prevention. (2022). Antibiotic resistance threats in the United States.